Hola,
Are you new here?

ERA PerMed

financed

ERA Net Cofund in Personalised Medicine

ERA PerMed will serve as a funding vehicle of topics identified in the Strategic Research and Innovation Agenda (SRIA) in Personalised Medicine and the Action Plan of ICPerMed. ERA PerMed will coordinate R&I efforts of the parti... see more

30/11/2023

ISCIII

32M€

Project Budget: 32M€

Project leader

INSTITUTO DE SALUD CARLOS III (ISCIII) No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 23M€

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 35 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2023-11-30

SC1-HCO-03-2017: Implementing the Strategic Research... Specific Challenge:By providing the right intervention to the right person at the right time, person...

I+D

Cerrada does 8 years

0% 30% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

35 Participantes

ISCIII

196.78K€ | Leader

EBIR ILUMINACION

182.44K€ | participant

MIZS

N.D. | participant

FRRB

1.39M€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 71 months Date Start: 2017-12-05
End date: 2023-11-30

Project leader

INSTITUTO DE SALUD CARLOS III (ISCIII) No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 23M€

Project Budget 32M€

participation deadline Sin fecha límite de participación.

Project description ERA PerMed will serve as a funding vehicle of topics identified in the Strategic Research and Innovation Agenda (SRIA) in Personalised Medicine and the Action Plan of ICPerMed. ERA PerMed will coordinate R&I efforts of the participating partners (funding agencies from EU, associate countries to H2020 and third countries). The main objective is planning, implementing, monitoring and disseminate up to four joint transnational calls (JTCs) tackling the value change in full to fund multidisciplinary transnational research projects covering each at least three slots of the value chain regarding Personalised Medicine. The ERA PerMed consortium is open to enlargement for the planned JTCs. According to funding scheme’s rules, ERA PerMed partners commit themselves to implement one call with top-up co-funding from the EC, and include funded project monitoring. Additionally, up to three non-cofunded calls will be carried, in order to broaden the scope of action of the efforts made by the EC and funding organizations to foster the Personalised Medicine Research Community and to be able to take into account recent changes within the landscape of personalised medicine, e.g. new developments of emerging technologies and societal challenges, which reinforces and amplifies the expected impact of ERA PerMed funding activity. Cooperation and links with ICPerMed and a dialogue with patient organisations, other European stakeholders and initiatives are crucial for both R&I and the implementation of their results and sustainability, which reinforces and amplifies the expected impact of ERA PerMed funding activity.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers